News Update

Dear Friend of Navigation Sciences,

I hope you are off to a productive start to 2025; the year is progressing quickly. I am pleased to provide an update on our activities to advance the development of the NaviSci™ System for precision surgical resection of lung and other soft tissue cancers.

Finance:

We are continuing efforts to close the Series B raise to complete the development of the NaviSci System, secure FDA clearance, and begin commercialization. Although there have been signs of increased activity in MedTech financing, the environment remains challenging.

As part of our fundraising efforts, at the **LSI USA '25, Emerging Medtech Summit at Dana Point (March 17-21)**, we will be presenting an update on the NavSci System's development progress and the growing opportunity for precision surgery technologies for the treatment of lung and other soft tissue cancers. Our presentation is on March 18 (10:55-11:04 AM PT, Track 3). The conference will provide an opportunity to meet potential investors and strategics. If you are attending, I would be happy to meet you there.

In addition, we have recently generated some visibility online. Navigation Sciences and our precision surgical oncology approach were featured on **Delta Healthtech Innovators** and **MIDI Product Development** podcasts. Dr. Jay Jagadeesan, Navigation's scientific co-founder, presented the System at the **Bengaluru Tech Summit** in India. We also gained recognition for the System as a significant innovation in precision surgery by being named as a nominee for **Galien Foundation's** 'Best Startup' award. The Prix Galien prizes are considered the Nobel Prize in healthcare and life sciences research and development.

Product Development:

We have always endeavored to run as a capital-efficient organization. We continue to focus on development activities on the critical path to an FDA filing. We are currently finishing work on the beta version of the System's software user interface.

Patents:

We recently enhanced our intellectual property position in Europe. The European Patent Office granted a key patent, EU3,041,427, covering the System's technology for resecting lung tumors, and we received notice that another European case was also allowed. The key difference between this and the already-issued European patent in this family is the application of the deformation algorithm calculating the resection margin and the addition of feedback (auditory, visual, and/or haptic) upon the encroachment of the instrument into the resection margin. The technology covered in the issued patent is central to the System's innovation. The first patent issued under the International Patent Cooperation Treaty (PCT) is being validated in the U.K., France, Germany, and Switzerland (including Lichtenstein). The issued and forthcoming patents join four U.S. patents in the Company's portfolio, with others pending. We've recently filed a new provisional patent application to protect further innovations in our deformation algorithm for lung segment mapping.

We recently developed a one-page summary of the Navigation Science investment opportunity, which can be found **here**. Please feel free to share it with your networks. Don't hesitate to reach out if there's interest in the Company. I'm happy to follow up at your convenience.

As always, thank you for your support.

Sincerely,

Alan Lucas, CEO, Navigation Sciences, Inc.
Alan.lucas@navigationsci.com +1-617-834-2829

Visit Our Website